Insights

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient…

Ask the Expert – Digital Therapeutics

Are We Transforming In The Right Way?

Articles

After FDA Approval, Can Gene Therapies Achieve Marketing Success?

Without a doubt, gene therapy is transforming healthcare by revolutionizing patient care from conventional treatment models to curative therapy models. There are more than 7,000 distinct types of rare and genetic diseases and 400+ million individuals…

Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review

How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better…

Challenges and Best Practices in Managing Value Based Contracts

Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare,…

white paper-insights
Gross-to-Net Improvement Through Holistic Revenue Enhancement

Consistent price increases have long been a staple of commercial strategy for pharmaceutical manufacturers. From this uplift in topline revenue, more sizable discounts can be provided to industry middlemen, like pharmacy benefit managers (PBMs), in order…

Navigating the Cycle of Supply Chain Complexity

As the industry evolves with new regulatory guidelines and product-specific handling requirements, manufacturers now require an agile business model with integrated distribution services. In his new point of view article, Danny Williams, explains how manufacturers can…

Global Biosimilar Competitor Assessment – Who Wins in Biosimilar Access and Why?

The introduction of biosimilar products has created interesting changes in payer behavior across the global markets. For both innovator and biosimilar companies, it has been an effort to understand the demands of payers and succeed in…

How do we pay for a cure?

Setting drug prices is a high-stakes endeavor, and that is especially true for the latest round of gene and curative products coming to market in Europe.  Drugmakers need to consider several factors that can help them…

Considerations for Compliance with the EU General Data Protection Regulation (GDPR)

The General Data Protection Regulation (GDPR) establishes a legal framework that sets guidelines for the collection and processing of personal information from individuals residing in the European Union (EU). GDPR compliance is a challenge for life…

Federal Enforcement of Clinical Pathways Resource Utilization Management

Providers order unnecessary tests for a variety of reasons: pressure from patients, fears of malpractice suit, not being knowledgeable about current “best” practices as well as for potential financial advantage for them or their health system.…

German and United Kingdom Physicians Express Frustration with Health System Challenges

This brief by Health Strategies Insights summarizes preliminary results compiled from twelve 30-minute, one-on-one, in-depth, telephone interviews with a mix of physician specialists from the United Kingdom (U.K.) and Germany. While the physicians discussed benefits of…